Cargando…

Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes

CONTEXT: Hyperglucagonemia may develop in type 2 diabetes due to obesity-prone hepatic steatosis (glucagon resistance). Markers of glucagon resistance (including the glucagon-alanine index) improve following diet-induced weight loss, but the partial contribution of lowering hepatic steatosis vs body...

Descripción completa

Detalles Bibliográficos
Autores principales: Kjeldsen, Sasha A S, Thomsen, Mads N, Skytte, Mads J, Samkani, Amirsalar, Richter, Michael M, Frystyk, Jan, Magkos, Faidon, Hansen, Elizaveta, Thomsen, Henrik S, Holst, Jens J, Madsbad, Sten, Haugaard, Steen B, Krarup, Thure, Wewer Albrechtsen, Nicolai J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561012/
https://www.ncbi.nlm.nih.gov/pubmed/37818402
http://dx.doi.org/10.1210/jendso/bvad122
_version_ 1785117832175943680
author Kjeldsen, Sasha A S
Thomsen, Mads N
Skytte, Mads J
Samkani, Amirsalar
Richter, Michael M
Frystyk, Jan
Magkos, Faidon
Hansen, Elizaveta
Thomsen, Henrik S
Holst, Jens J
Madsbad, Sten
Haugaard, Steen B
Krarup, Thure
Wewer Albrechtsen, Nicolai J
author_facet Kjeldsen, Sasha A S
Thomsen, Mads N
Skytte, Mads J
Samkani, Amirsalar
Richter, Michael M
Frystyk, Jan
Magkos, Faidon
Hansen, Elizaveta
Thomsen, Henrik S
Holst, Jens J
Madsbad, Sten
Haugaard, Steen B
Krarup, Thure
Wewer Albrechtsen, Nicolai J
author_sort Kjeldsen, Sasha A S
collection PubMed
description CONTEXT: Hyperglucagonemia may develop in type 2 diabetes due to obesity-prone hepatic steatosis (glucagon resistance). Markers of glucagon resistance (including the glucagon-alanine index) improve following diet-induced weight loss, but the partial contribution of lowering hepatic steatosis vs body weight is unknown. OBJECTIVE: This work aimed to investigate the dependency of body weight loss following a reduction in hepatic steatosis on markers of glucagon resistance in type 2 diabetes. METHODS: A post hoc analysis was conducted from 2 previously published randomized controlled trials. We investigated the effect of weight maintenance (study 1: isocaloric feeding) or weight loss (study 2: hypocaloric feeding), both of which induced reductions in hepatic steatosis, on markers of glucagon sensitivity, including the glucagon-alanine index measured using a validated enzyme-linked immunosorbent assay and metabolomics in 94 individuals (n = 28 in study 1; n = 66 in study 2). Individuals with overweight or obesity with type 2 diabetes were randomly assigned to a 6-week conventional diabetes (CD) or carbohydrate-reduced high-protein (CRHP) diet within both isocaloric and hypocaloric feeding-interventions. RESULTS: By design, weight loss was greater after hypocaloric compared to isocaloric feeding, but both diets caused similar reductions in hepatic steatosis, allowing us to investigate the effect of reducing hepatic steatosis with or without a clinically relevant weight loss on markers of glucagon resistance. The glucagon-alanine index improved following hypocaloric, but not isocaloric, feeding, independently of macronutrient composition. CONCLUSION: Improvements in glucagon resistance may depend on body weight loss in patients with type 2 diabetes.
format Online
Article
Text
id pubmed-10561012
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105610122023-10-10 Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes Kjeldsen, Sasha A S Thomsen, Mads N Skytte, Mads J Samkani, Amirsalar Richter, Michael M Frystyk, Jan Magkos, Faidon Hansen, Elizaveta Thomsen, Henrik S Holst, Jens J Madsbad, Sten Haugaard, Steen B Krarup, Thure Wewer Albrechtsen, Nicolai J J Endocr Soc Clinical Research Article CONTEXT: Hyperglucagonemia may develop in type 2 diabetes due to obesity-prone hepatic steatosis (glucagon resistance). Markers of glucagon resistance (including the glucagon-alanine index) improve following diet-induced weight loss, but the partial contribution of lowering hepatic steatosis vs body weight is unknown. OBJECTIVE: This work aimed to investigate the dependency of body weight loss following a reduction in hepatic steatosis on markers of glucagon resistance in type 2 diabetes. METHODS: A post hoc analysis was conducted from 2 previously published randomized controlled trials. We investigated the effect of weight maintenance (study 1: isocaloric feeding) or weight loss (study 2: hypocaloric feeding), both of which induced reductions in hepatic steatosis, on markers of glucagon sensitivity, including the glucagon-alanine index measured using a validated enzyme-linked immunosorbent assay and metabolomics in 94 individuals (n = 28 in study 1; n = 66 in study 2). Individuals with overweight or obesity with type 2 diabetes were randomly assigned to a 6-week conventional diabetes (CD) or carbohydrate-reduced high-protein (CRHP) diet within both isocaloric and hypocaloric feeding-interventions. RESULTS: By design, weight loss was greater after hypocaloric compared to isocaloric feeding, but both diets caused similar reductions in hepatic steatosis, allowing us to investigate the effect of reducing hepatic steatosis with or without a clinically relevant weight loss on markers of glucagon resistance. The glucagon-alanine index improved following hypocaloric, but not isocaloric, feeding, independently of macronutrient composition. CONCLUSION: Improvements in glucagon resistance may depend on body weight loss in patients with type 2 diabetes. Oxford University Press 2023-09-21 /pmc/articles/PMC10561012/ /pubmed/37818402 http://dx.doi.org/10.1210/jendso/bvad122 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Research Article
Kjeldsen, Sasha A S
Thomsen, Mads N
Skytte, Mads J
Samkani, Amirsalar
Richter, Michael M
Frystyk, Jan
Magkos, Faidon
Hansen, Elizaveta
Thomsen, Henrik S
Holst, Jens J
Madsbad, Sten
Haugaard, Steen B
Krarup, Thure
Wewer Albrechtsen, Nicolai J
Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes
title Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes
title_full Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes
title_fullStr Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes
title_full_unstemmed Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes
title_short Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes
title_sort markers of glucagon resistance improve with reductions in hepatic steatosis and body weight in type 2 diabetes
topic Clinical Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561012/
https://www.ncbi.nlm.nih.gov/pubmed/37818402
http://dx.doi.org/10.1210/jendso/bvad122
work_keys_str_mv AT kjeldsensashaas markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes
AT thomsenmadsn markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes
AT skyttemadsj markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes
AT samkaniamirsalar markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes
AT richtermichaelm markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes
AT frystykjan markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes
AT magkosfaidon markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes
AT hansenelizaveta markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes
AT thomsenhenriks markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes
AT holstjensj markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes
AT madsbadsten markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes
AT haugaardsteenb markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes
AT krarupthure markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes
AT weweralbrechtsennicolaij markersofglucagonresistanceimprovewithreductionsinhepaticsteatosisandbodyweightintype2diabetes